Shopping Cart
- Remove All
Your shopping cart is currently empty
BRD0705
BRD0705 is a potent, orally active GSK3α inhibitor with high selectivity (IC50: 66 nM; Kd: 4.8 μM), demonstrating an 8-fold higher selectivity for GSK3α compared to GSK3β (IC50: 515 nM).
Catalog No. T10606Cas No. 2056261-41-5
Select Batch
Purity:99.59%
Contact us for more batch information
BRD0705
Catalog No. T10606Cas No. 2056261-41-5
BRD0705 is a potent, orally active GSK3α inhibitor with high selectivity (IC50: 66 nM; Kd: 4.8 μM), demonstrating an 8-fold higher selectivity for GSK3α compared to GSK3β (IC50: 515 nM).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $151 | In Stock | |
| 2 mg | $211 | In Stock | |
| 5 mg | $322 | In Stock | |
| 10 mg | $466 | In Stock | |
| 25 mg | $693 | In Stock | |
| 50 mg | $972 | In Stock | |
| 100 mg | $1,300 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $351 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BRD0705"
4-Chloro-2'-bromoacetophenone
T8908536-38-9
4-Chloro-2'-bromoacetophenone against glycogen synthase kinase-3 (GSK-3beta).
- $30
Size
QTY
CHIR-99021
Cited
Laduviglusib, CT99021, CHIR-99021
T2310252917-06-9
CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
- $36
Size
QTY
CitedCromolyn sodium
Disodium Cromoglycate, FPL 670 (Cromolyn) Disodium, FPL-670, Sodium cromoglycate
T126015826-37-6
Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.
- $48
Size
QTY
GSK-3 Inhibitor 5
4-Cyanophenacyl bromide
T7755420099-89-2
GSK-3 Inhibitor 5 (4-Cyanophenacyl bromide) is a ketone derivative that is used as an intermediate in pharmaceuticals and organic synthesis, and inhibits glycogen synthase kinase 3 (GSK-3).
- $29
Size
QTY
GSK 3 Inhibitor IX Cited
BIO, GSK 3 IX, 6-BIO, 6-Bromoindirubin-3'-oxime, MLS 2052, 6-bromoindirubin-3-oxime
T1917667463-62-9
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
- $37
Size
QTY
CitedAT7519 Cited
T6205844442-38-2
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
- $52
Size
QTY
CitedSNS-032 Cited
SNS032, BMS-387032
T6049345627-80-7
SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM), exhibiting 10- and 20-fold selectivity over CDK1 and CDK4, respectively. It is also sensitive to CDK7 (IC50: 62 nM) and CDK9 (IC50: 4 nM), with no effect on CDK6.
- $43
Size
QTY
CitedMeBIO
T21966667463-95-8
MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.
- $33
Size
QTY
5-Bromoindole
T747310075-50-0
5-bromoindole is a potential inhibitor of glycogen synthase kinase 3 (GSK-3)and an important pharmaceutical chemical intermediate
- $38
Size
QTY
1-Azakenpaullone
azakenpaullone
T6358676596-65-9
1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.
- $43
Size
QTY
PHA-767491 Cited
CAY10572, PHA767491, PHA 767491
T6206845714-00-3
PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
- $30
Size
QTY
CitedCHIR-99021 HCl Cited
CT99021 HCl, Laduviglusib HCl
T2310L1797989-42-4
CHIR-99021 HCl (Laduviglusib HCl) is a highly potent and selective inhibitor of GSK-3α/β, with IC50 values of 10 nM and 6.7 nM respectively. It demonstrates remarkable selectivity for GSK-3, with over 500-fold selectivity over CDC2, ERK2, and other protein kinases. Additionally, CHIR-99021 HCl serves as a robust activator of the Wnt/β-catenin signaling pathway. Moreover, it exhibits the ability to enhance self-renewal in both mouse and human embryonic stem cells. Furthermore, CHIR-99021 HCl induces autophagy [1] [2] [3].
- $30
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
| Description | BRD0705 is a potent, orally active GSK3α inhibitor with high selectivity (IC50: 66 nM; Kd: 4.8 μM), demonstrating an 8-fold higher selectivity for GSK3α compared to GSK3β (IC50: 515 nM). |
| Targets&IC50 | GSK-3α:4.8 μM (Kd), GSK-3α:66 nM, GSK-3β (WT):515 nM |
| In vitro | BRD0705 displays excellent selectivity in a penal of 311 kinases, the CDK family of kinases (CDK2, 3 and 5) are next most potently inhibits at values of 6.87 μM, 9.74 μM and 9.20 μM (87-fold, 123-fold and 116-fold selectivity relative to GSK3α). BRD0705 (10-40 μM; 2-24 hours; U937 cells) treatment impairs GSK3α Tyr279 phosphorylation in a time-and concentration-dependent manner without affecting GSK3β Tyr216 phosphorylation. BRD0705 impairs AML colony formation in all six tested cell lines, MOLM13, TF-1, U937, MV4-11, HL-60, and NB4, in a concentration-dependent manner, as opposed to BRD3731 which impairs colony formation in TF-1 while increasing colony-forming ability in the MV4-11 cell line. |
| In vivo | In AML mouse models, BRD0705 (30 mg/kg; oral gavage; twice daily; NSG mice) treatment impairs leukemia initiation and prolongs survival. |
| Molecular Weight | 321.42 |
| Formula | C20H23N3O |
| Cas No. | 2056261-41-5 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 300 mg/mL (933.36 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy BRD0705 | purchase BRD0705 | BRD0705 cost | order BRD0705 | BRD0705 chemical structure | BRD0705 in vivo | BRD0705 in vitro | BRD0705 formula | BRD0705 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.